CVI Holdings’s ReShape Lifesciences Inc. Common Stock RSLS Stock Holding History

CVI Holdings’s Portfolio RSLS Stock Details RSLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-118	Closed	-$38K	–	64
2018 Q2	$38K	Buy	+118	New	+$101K	0.05%	41

Other funds holding RSLS

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IBT

International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CVI Holdings's RSLS Position: Q3 2018 in Review

CVI Holdings sold out of ReShape Lifesciences Inc. Common Stock (RSLS) in Q3 2018, closing a stake of 118 shares — an estimated $38K sold.

CVI Holdings first reported a position in RSLS in Q2 2018 and held it in 1 quarter. The position peaked at $38K in Q2 2018. 15 funds tracked by Wall St. Rank hold RSLS as of Q3 2018.

CVI Holdings reported no remaining ReShape Lifesciences Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
CVI Holdings sold 118 ReShape Lifesciences Inc. Common Stock shares in Q3 2018, an estimated $38K.
CVI Holdings first reported a position in ReShape Lifesciences Inc. Common Stock in Q2 2018 and held it in 1 quarter.
CVI Holdings's ReShape Lifesciences Inc. Common Stock position peaked at $38K in Q2 2018.
15 funds tracked by Wall St. Rank held ReShape Lifesciences Inc. Common Stock as of Q3 2018.

Based on CVI Holdings's 13F filing for Q3 2018, filed 14 Nov 2018.